Claudia Brogsitter
Overview
Explore the profile of Claudia Brogsitter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
178
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luna Mass A, Runge R, Wetzig K, Huebinger L, Brogsitter C, Kotzerke J
Pharmaceuticals (Basel)
. 2024 Nov;
17(11).
PMID: 39598362
New therapeutic strategies for metastatic castration-resistant prostate cancer (mCRPC) have been developed in the past to achieve the best response rates. Most recently, the use of combination therapies has been...
2.
Hubinger L, Wetzig K, Runge R, Hartmann H, Tillner F, Tietze K, et al.
Pharmaceutics
. 2024 Apr;
16(4).
PMID: 38675195
This work investigates the proposed enhanced efficacy of photodynamic therapy (PDT) by activating photosensitizers (PSs) with Cherenkov light (CL). The approaches of Yoon et al. to test the effect of...
3.
Kastner D, Braune A, Brogsitter C, Freudenberg R, Kotzerke J, Michler E
EJNMMI Phys
. 2024 Apr;
11(1):35.
PMID: 38581559
Background: The administration of a Ho scout dose is available as an alternative to Tc particles for pre-treatment imaging in Selective Internal Radiation Therapy (SIRT). It has been reported that...
4.
Freudenberg R, Kastner D, Kotzerke J, Brogsitter C
Nuklearmedizin
. 2024 Jan;
63(2):62-68.
PMID: 38262471
No abstract available.
5.
Miederer M, Benesova-Schafer M, Mamat C, Kastner D, Pretze M, Michler E, et al.
Pharmaceuticals (Basel)
. 2024 Jan;
17(1).
PMID: 38256909
The use of radionuclides for targeted endoradiotherapy is a rapidly growing field in oncology. In particular, the focus on the biological effects of different radiation qualities is an important factor...
6.
Runge R, Reissig F, Herzog N, Oehme L, Brogsitter C, Kotzerke J
Pharmaceuticals (Basel)
. 2023 Dec;
16(12).
PMID: 38139846
Background: The combination of platinum-containing cytostatic drugs with different radiation qualities has been studied for years. Despite their massive side effects, these drugs still belong to the therapeutic portfolio in...
7.
Michler E, Kastner D, Brogsitter C, Pretze M, Hartmann H, Freudenberg R, et al.
Eur J Nucl Med Mol Imaging
. 2023 Nov;
51(5):1490-1492.
PMID: 37991526
No abstract available.
8.
Krocher A, Folprecht G, Winzer R, Sergon M, Bornhauser M, Kotzerke J, et al.
Case Rep Oncol
. 2023 Oct;
16(1):1166-1171.
PMID: 37900794
Based on the results of the NETTER-1 trial, peptide receptor radionuclide therapy with Lutetium-177 (Lu) - DOTATATE is authorized for the treatment of neuroendocrine tumors (NET) grade 1 (G1) and...
9.
Pretze M, Kotzerke J, Freudenberg R, Brogsitter C
J Nucl Med
. 2023 Aug;
64(10):1663.
PMID: 37536739
No abstract available.
10.
Hartmann H, Andreeff M, Claussnitzer J, Kotzerke J, Brogsitter C
Rofo
. 2023 May;
195(7):605-612.
PMID: 37160149
Methods: In 147 patients after RIT and their relatives, the dosage was measured over 14 days with different measuring systems. Finger ring dosimeters (FRD) were worn during the whole day,...